Alnylam Reports EMA COMP Positive Opinion For ALN-TTRsc02 - Quick Facts

Shutterstock photo

(RTTNews.com) - Alnylam Pharmaceuticals, Inc. ( ALNY ) announced the European Medicines Agency Committee for Orphan Medicinal Products has issued a positive opinion recommending ALN-TTRsc02, an investigational, subcutaneously administered RNAi therapeutic, for designation as an orphan medicinal product for the treatment of transthyretin (TTR)-mediated amyloidosis.

The safety and efficacy of ALN-TTRsc02 have not been evaluated by the U.S. FDA, European Medicines Agency or any other health authority.

Read the original article on RTTNews (http://www.rttnews.com/2884621/alnylam-reports-ema-comp-positive-opinion-for-aln-ttrsc02-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: Stocks , Politics
Referenced Symbols: ALNY

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?